ArticleGenes & genomics2026
A multi-omics analysis of a succinylation-associated gene-expression signature in clear cell renal cell carcinoma: prognostic significance and the immune-metabolic microenvironment.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) exhibits significant metabolic alterations. Protein succinylation, a metabolite-induced post-translational modification, plays a vital role in cellular metabolism and tumor biology.
objectiveTo characterize the succinylation-associated transcriptional signature and its clinical relevance in ccRCC.
methodsWe developed a succinylation-associated transcriptional score based on a literature-curated 20-gene panel using the TCGA-KIRC RNA-seq dataset, with prognostic validation in two independent cohorts (E-MTAB-1980 and CPTAC). The tumor immune microenvironment was analyzed via ESTIMATE, CIBERSORT, and ssGSEA. Cellular localization of the score was investigated using single-cell and spatial transcriptomics. Functional enrichment, drug response analyses, and qPCR validation were also performed.
resultsTumor tissues demonstrated significantly reduced succinylation-associated transcriptional scores compared to normal counterparts, with higher scores correlating with improved clinical outcomes. Multivariate analyses supported the independent prognostic value of the succinylation-associated transcriptional score for overall survival in the TCGA and validation datasets. Interestingly, low-score tumors exhibited a transcriptionally "immune-hot" phenotype, characterized by enhanced immune cell infiltration and elevated immune checkpoint expression. Single-cell and spatial transcriptomic analyses suggested that tumor cells primarily contributed to the succinylation-associated transcriptional score. Functional assessments revealed that high scores were associated with oxidative phosphorylation and fatty acid metabolism, while low scores correlated with pro-tumorigenic signaling pathways. Computational drug sensitivity analysis identified exploratory associations that may inform future therapy stratification based on succinylation profiles.
conclusionThe succinylation-associated transcriptional score represents a promising biomarker candidate in ccRCC, showing associations with prognosis and key metabolic-immune features. Our study underscores the role of succinylation in ccRCC biology and provides a framework for metabolic subtyping that may inform future biological and clinical stratification studies.
Indexed as
Identifiers
42257998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.